Pretransplant Patient Characteristics
| . | AML-1°CR (n = 31) . | AML-2°CR (n = 8) . |
|---|---|---|
| Age [yr] | ||
| Median [range] | 36.7 [16.5-51.5] | 32.9 [14.8-54.8] |
| 14-19 | 1 | 1 |
| 20-29 | 7 | 2 |
| 30-39 | 13 | 3 |
| ≥40 | 10 | 2 |
| FAB classification | ||
| M0 | 1 | |
| M1 | 5 | 1 |
| M2 | 12 | 1 |
| M3 | 1 | 3 |
| M4 | 5 | 1 |
| M5 | 4 | |
| M6 | 1 | |
| Unknown/indeterminate | 2 | 2 |
| Karyotype | ||
| Normal | 7 | |
| t[8;21]-150 | 7 | 1 |
| t[15;17]-150 | 1 | 3 |
| inv[16]-150 | 1 | |
| trisomy 8 | 4 | |
| Other pseudodiploid | 2 | 1 |
| Other hyperdiploid | 1 | |
| Not available | 8 | 3 |
| No. of induction courses to achieve CR | ||
| 1 | 23 | n/a |
| 2 | 8 | n/a |
| No. of consolidation courses | ||
| 0 | 5 | n/a |
| 1 | 21 | n/a |
| 2 | 5 | n/a |
| Elapsed months to BMT, median [range] | ||
| From diagnosis | 3.9 [2.4-8.8] | n/a |
| From CR | 2.3 [0.6-7.8] | n/a |
| Duration of first CR, months, median [range] | n/a | 11.44 [1.87-109] |
| . | AML-1°CR (n = 31) . | AML-2°CR (n = 8) . |
|---|---|---|
| Age [yr] | ||
| Median [range] | 36.7 [16.5-51.5] | 32.9 [14.8-54.8] |
| 14-19 | 1 | 1 |
| 20-29 | 7 | 2 |
| 30-39 | 13 | 3 |
| ≥40 | 10 | 2 |
| FAB classification | ||
| M0 | 1 | |
| M1 | 5 | 1 |
| M2 | 12 | 1 |
| M3 | 1 | 3 |
| M4 | 5 | 1 |
| M5 | 4 | |
| M6 | 1 | |
| Unknown/indeterminate | 2 | 2 |
| Karyotype | ||
| Normal | 7 | |
| t[8;21]-150 | 7 | 1 |
| t[15;17]-150 | 1 | 3 |
| inv[16]-150 | 1 | |
| trisomy 8 | 4 | |
| Other pseudodiploid | 2 | 1 |
| Other hyperdiploid | 1 | |
| Not available | 8 | 3 |
| No. of induction courses to achieve CR | ||
| 1 | 23 | n/a |
| 2 | 8 | n/a |
| No. of consolidation courses | ||
| 0 | 5 | n/a |
| 1 | 21 | n/a |
| 2 | 5 | n/a |
| Elapsed months to BMT, median [range] | ||
| From diagnosis | 3.9 [2.4-8.8] | n/a |
| From CR | 2.3 [0.6-7.8] | n/a |
| Duration of first CR, months, median [range] | n/a | 11.44 [1.87-109] |
Abbreviation: n/a, not applicable.
Associated with favorable outcomes after chemotherapy alone.19